Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.33 |
| ▸ | AR | P10275 | 4/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2325391 | 0.90 | AR (0.40) | NOTUMTRPA1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2325071 | 0.86 | ACHE (0.34) | NOTUMTRPA1CHRNB2CHRNA4SLC6A4 | |
| SCHEMBL2325632 | 0.84 | TRPA1 (0.43) | NOTUMTRPA1CHRNB2CHRNA4RBP4 | |
| SCHEMBL1549035 | 0.82 | AR (0.41) | NOTUMTRPA1ARRBP4 | |
| SCHEMBL2322937 | 0.81 | CYP11B1 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A4 | |
| SCHEMBL2321845 | 0.79 | CYP11B1 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A4 | |
| SCHEMBL2322920 | 0.79 | NISCH (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A4 | |
| SCHEMBL2325039 | 0.79 | CDK9 (0.40) | HTR2A | |
| SCHEMBL2324690 | 0.76 | TRPA1 (0.35) | TRPA1CHRNB2CHRNA4SLC6A4RBP4 | |
| SCHEMBL1384167 | 0.76 | TRPA1 (0.47) | NOTUMTRPA1RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | claimed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | claimed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | NOTUM 2418/4885TRPA1 4582/4885CHRNB2 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.